Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis
Journal of Cosmetic Dermatology · 2026-03 · 25 (3)
DOI: 10.1111/jocd.70799 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 19.03.2026. Verfasst von Chang Shu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, Peo…. Hauptthemen laut MEDLINE: Granuloma, Mesotherapy, Piperidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Key Clinical Specialty Construction Project, National Key Clinical Specialty Project of China.
Abstract (Originalsprache)
Background
Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients.
Objective
This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy.
Methods
This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed.
Results
All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up.
Conclusion
Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, People's Republic of China.
ORCID-Profile: Chang Shu, Tao Zhang, Jia-Wei Liu, Chen-Yu Zhu, Rou-Yu Fang, Qiu-Ning Sun, Nian Li, Feng Li
Förderung
- Beijing Key Clinical Specialty Construction Project
- National Key Clinical Specialty Project of China
Zitieren
APA
Shu, C., Zhang, T., Liu, J. W., Zhu, C. Y., Fang, R. Y., Sun, Q. N., Li, N., & Li, F. (2026). Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis. Journal of Cosmetic Dermatology, 25(3). https://doi.org/10.1111/jocd.70799
Vancouver
Shu C, Zhang T, Liu JW, Zhu CY, Fang RY, Sun QN, et al. Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis. Journal of Cosmetic Dermatology. 2026;25(3). doi:10.1111/jocd.70799
BibTeX
@article{Shu2026,
author = {Shu, Chang and Zhang, Tao and Liu, Jia-Wei and Zhu, Chen-Yu and Fang, Rou-Yu and Sun, Qiu-Ning and Li, Nian and Li, Feng},
title = {Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {3},
doi = {10.1111/jocd.70799}
}
EUVIMED